• 1
    Friedman EA, Shyh TP, Beyer MM, et al. Posttransplant diabetes in kidney transplant recipients. Am J Nephrol 1985; 5: 196.
  • 2
    Sumrani NB, Delaney V, Ding ZK, et al. Diabetes mellitus after renal transplantation in the cyclosporine era: an analysis of risk factors. Transplantation 1989; 47: 278.
  • 3
    Vesco L, Busson M, Bedrossian J, et al. Diabetes mellitus after renal transplantation. Transplantation 1996; 61: 1475.
  • 4
    Montori VM, Basu A, Erwin PJ, Velosa JA, Gabriel SE, Kudva YC. Posttransplantation diabetes: a systematic review of the literature. Diabetes Care 2002; 25: 583.
  • 5
    Pirsch JD, Miller J, Deierhoi MH, Vincenti F, Filo RS. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. Transplantation 1997; 63: 977.
  • 6
    Hirano Y, Hisatomi A, Ohara K, Noguchi H. The effects of FK506 and cyclosporine on the exocrine function of the rat pancreas. Transplantation 1992; 54: 883.
  • 7
    Tamura K, Fujimura T, Tsutsumi T, et al. Transcriptional inhibition of insulin by FK506 and possible involvement of FK506 binding-protein-12 in pancreatic [beta]-cell. Transplantation 1995; 59: 1606.
  • 8
    Mudalier S, Henry RR. New oral therapies for type 2 diabetes mellitus: the glitazones or insulin sensitisers. Ann Rev Med 2001; 52: 239.
  • 9
    First MR, Gerber DA, Hariharan S, Kaufman DB, Shapiro R. Posttransplant diabetes mellitus in kidney allograft recipients: incidence, risk factors, and management. Transplantation 2002; 73: 379.
  • 10
    Hjelmesath J, Jenssen T, Hartmann A. Diagnosing PTDM. Transplantation 2003; 75: 1761.
  • 11
    Baldwin D, Duffin KE. Rosiglitazone treatment of diabetes mellitus after solid organ transplantation. Transplantation 2004; 77: 1009.
  • 12
    Davidson J, Wilkinson A, Dantal J, et al. New-onset diabetes after transplantation: 2003 international consensus guidelines. Transplantation 2003; 75(Suppl): SS3.
  • 13
    Wolffenbuttel BHR, Gomis R, Squatrito S, Jones NP, Patwardhan RN. Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycemic control in type 2 diabetic patients. Diabet Med 2000; 17: 40.
  • 14
    Raskin P, Rappaport EB, Cole ST, Yan Y, Patwardhan R, Freed MI. Rosiglitazone short-term monotherapy lowers fasting and post-prandial glucose in patients with type II diabetes. Diabetologia 2000; 43: 278.
  • 15
    Lin SH, Lin YF, Kuo SW, Hsu YJ, Hung YJ. Rosiglitazone improves glucose metabolism in nondiabetic uremic patients on CAPD. Am J Kid Dis 2003; 42: 774.
  • 16
    Thompson-Culkin K, Zussman B, Miller AK, Freed MI. Pharmacokinetics of rosiglitazone in patients with end-stage renal disease. J Int Med Res 2002; 30: 391.